Two Part (Phase1b/ Phase3) Trial of Subcutaneous Dostarlimab Plus Carboplatin-Paclitaxel in Participants With Primary Advanced or Recurrent Endometrial Cancer (SAPPHIRE)
An Open-label, Multicenter, 2-Part Study: A Phase 1b Dose Selection Followed by a Randomized Phase 3 to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Dostarlimab Plus Carboplatin-Paclitaxel Versus Intravenous Dostarlimab Plus Carboplatin-Paclitaxel in Participants With Primary Advanced or Recurrent Endometrial Cancer (SAPPHIRE)
This is an open-label study, meaning both the researchers and participants will know which treatment is being given.
The study has two parts. In Part 1, researchers will identify the most suitable SC dose. In Part 2, participants will be randomly assigned by chance to receive dostarlimab as either an SC injection or an IV infusion. All participants will also receive carboplatin and paclitaxel. Treatment may continue for up to 3 years, with participants closely monitored throughout the study.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Phase
- Phase 3
Contacts et emplacements
Coordonnées de l'étude
- Nom: US GSK Clinical Trials Call Center
- Numéro de téléphone: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
Sauvegarde des contacts de l'étude
- Nom: EU GSK Clinical Trials Call Center
- Numéro de téléphone: +44 (0) 20 89904466
- E-mail: GSKClinicalSupportHD@gsk.com
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Participant is at least 18 years of age (or the legal age of consent in the jurisdiction in which the trial is taking place) at the time of signing the Informed Consent Form (ICF).
- Participant has primary Stage III or Stage IV disease or first recurrent EC.
- Participant must have a documented Mismatch repair (MMR)/Microsatellite Instability (MSI) status.
- Participant is capable of giving signed informed consent, including compliance with the requirements and restrictions listed in the ICF and in the protocol.
- Participant has an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 for Part 1 and an ECOG performance status of 0 or 1 for Part 2.
- Participant has adequate organ function.
Exclusion Criteria:
- Participant has history of or active autoimmune disease that has required systemic treatments within the 2 years prior to screening.
- Participant has a history of severe allergic and/or anaphylactic reactions to chimeric, human or humanized antibodies, fusion proteins, or known hypersensitivity to carboplatin, paclitaxel or dostarlimab components or excipients.
- Participant has received prior therapy with anti-programmed death protein 1 (PD-1), anti-programmed cell death ligand 1 (PD-L1), or anti-PD-L2 agent.
- Participant has known uncontrolled brain or central nervous system (CNS) metastases.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation séquentielle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Part 1 (Phase 1b) SC dostarlimab and IV dostarlimab
Participants will receive SC dostarlimab in Cohorts 1, 2, 4, 5 and 6, at different doses, to determine the doses of SC dostarlimab that will yield drug exposures comparable to approved IV dosing regimens. Participants in Cohort 3 will receive IV dostarlimab. Participants in all cohorts will receive carboplatin and paclitaxel. After 6 cycles, all participants will receive IV dostarlimab for up to 3 years until progression, death, or intolerable toxicities. |
Dostarlimab will be administered as SC injection and IV infusion Carboplatin and paclitaxel will be administered as an IV infusion |
|
Expérimental: Part 2 (Phase 3): SC dostarlimab (experimental) or IV dostarlimab (standard of care)
Eligible participants will be randomly assigned to receive either SC dostarlimab or IV dostarlimab (standard of care arm) in a 1:1 ratio. Participants randomized to the experimental arm will receive SC dostarlimab in combination with carboplatin and paclitaxel for 6 cycles, followed by SC dostarlimab monotherapy for up to 3 years of treatment in total. Participants randomized to the standard of care arm will receive IV dostarlimab in combination with carboplatin and paclitaxel for 6 cycles, followed by IV dostarlimab monotherapy for up to 3 years of treatment in total. |
Dostarlimab will be administered as SC injection and IV infusion Carboplatin and paclitaxel will be administered as an IV infusion |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
|---|---|
|
Part 1: Serum Trough Concentration (Ctrough) After First Dose of Dostarlimab
Délai: Up to 42 days
|
Up to 42 days
|
|
Part 1: Area Under the Concentration-time Curve (AUC) of Dostarlimab
Délai: Up to 42 days
|
Up to 42 days
|
|
Part 2: Observed Ctrough of Dostarlimab
Délai: Up to 168 days
|
Up to 168 days
|
|
Part 2: Model-predicted (MP) AUC of Dostarlimab
Délai: Up to 21 days
|
Up to 21 days
|
|
Part 2: MP AUC of Dostarlimab
Délai: Up to 168 days
|
Up to 168 days
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Part 1: Ctrough of Dostarlimab
Délai: Up to 42 days
|
Up to 42 days
|
|
|
Part 1: AUC of Dostarlimab
Délai: Up to 42 days
|
Up to 42 days
|
|
|
Part 1: Maximum Observed Concentration (Cmax) of Dostarlimab
Délai: Up to 42 days
|
Up to 42 days
|
|
|
Part 1: Time to Peak Drug Concentration (Tmax) of Dostarlimab
Délai: Up to 42 days
|
Up to 42 days
|
|
|
Parts 1 and 2: Number of Participants Experiencing Adverse Events (AEs), Serious AEs (SAEs), Treatment-emergent AEs (TEAEs) and Immune-mediated AEs (imAEs)
Délai: Up to 39 months
|
Up to 39 months
|
|
|
Parts 1 and 2: Number of Participants with TEAEs Leading to Infusion or Injection Interruption, Dose Modifications, Trial Intervention Discontinuation, or Death
Délai: Up to 39 months
|
Up to 39 months
|
|
|
Parts 1 and 2: Confirmed Overall Response Rate (ORR)
Délai: Up to 3 years
|
Confirmed ORR is defined as the percentage of participants reaching confirmed complete response (CR) or confirmed partial response (PR) per RECIST 1.1 by blinded independent central review (BICR) and investigator assessment |
Up to 3 years
|
|
Parts 1 and 2: Duration of Response (DoR)
Délai: Up to 3 years
|
DoR per RECIST 1.1 by BICR and investigator assessment is defined as the time from the date of first documented objective response of CR or PR that is subsequently confirmed until the date of first documented progressive disease (PD) or death due to any cause, whichever comes first |
Up to 3 years
|
|
Parts 1 and 2: Progression-free Survival (PFS)
Délai: Up to 3 years
|
PFS is defined as the time from the date of randomization to the date of first documented objective tumor progression per RECIST 1.1 by BICR and investigator assessment or death due to any cause, whichever comes first |
Up to 3 years
|
|
Parts 1 and 2: Overall Survival (OS)
Délai: Up to 3 years
|
OS is defined as the time from the date of randomization to the date of death due to any cause |
Up to 3 years
|
|
Part 1: Number of Participants with Antidrug Antibody (ADAs) against Dostarlimab
Délai: Up to 39 months
|
Up to 39 months
|
|
|
Part 2: Number of Participants with ADAs against Dostarlimab
Délai: Up to 3 years
|
Up to 3 years
|
|
|
Part 2: MP Ctrough of Dostarlimab
Délai: Up to 168 days
|
Up to 168 days
|
|
|
Part 2: MP Ctrough at Steady State of Dostarlimab
Délai: Up to 168 days
|
Up to 168 days
|
|
|
Part 2: MP AUC at Steady State of Dostarlimab
Délai: Up to 168 days
|
Up to 168 days
|
|
|
Part 2: MP Cmax of Dostarlimab
Délai: Up to 168 days
|
Up to 168 days
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Directeur d'études: GSK Clinical Trials, GlaxoSmithKline
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Maladies urogénitales
- Maladies génitales
- Tumeurs urogénitales
- Tumeurs par site
- Tumeurs
- Maladies urogénitales féminines
- Maladies urogénitales féminines et complications de la grossesse
- Maladies utérines
- Maladies génitales, femme
- Tumeurs génitales, femme
- Tumeurs utérines
- Tumeurs de l'endomètre
- Produits chimiques organiques
- Hydrocarbures
- Cycloparaffines
- Hydrocarbures, alicyclique
- Hydrocarbures, cyclique
- Terpènes
- Complexes de coordination
- Taxes
- Cyclodécanes
- Diterpènes
- Carboplatine
- Paclitaxel
- dostarlimab
Autres numéros d'identification d'étude
- 300118
- 2025 (Subvention/contrat des NIH des États-Unis)
- 2025-525060-15-00 (Ctis)
- EN-35 (Autre identifiant: ENGOT Number)
- GOG-3125 (Autre identifiant: GOG Number)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/gsk-patient-level-data-sharing-july2025.pdf
Délai de partage IPD
Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.
Critères d'accès au partage IPD
Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.
Type d'informations de prise en charge du partage d'IPD
- PROTOCOLE D'ÉTUDE
- SÈVE
- CIF
- RSE
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .